Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Program as Combination Agent with Standard Chemotherapies and Pivotal Lung Cancer Trial Scheduled to Begin Early Next Year -

CHICAGO and SUNNYVALE, Calif. June 01, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced promising preliminary results from an open-label Phase 2 clinical trial of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead cancer therapeutic candidate, as a second-line treatment for patients with recurrent, metastatic non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were published in the proceedings of the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) taking place this week in Chicago.

"These results indicate that Xcytrin is an active, well-tolerated drug for treatment of recurrent NSCLC," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "The response rate and survival observed in this trial are comparable to currently approved second-line therapies for NSCLC and support our strategy to conduct multiple ongoing Phase 2 studies of Xcytrin in combination with standard therapies and move into a pivotal trial for this indication early next year. In addition, we are continuing to pursue our new drug application for Xcytrin to treat patients with brain metastases from NSCLC. We believe Xcytrin's selectivity, novel mechanism of action, magnetic resonance imaging detectability, and non-overlapping toxicity with other agents make it an appealing drug to study in combination with other therapies for a broad range of cancers."

The abstract, "A phase II trial of motexafin gadolinium (MGd) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-based chemotherapy: Preliminary results of Stage 1," described interim results from a Phase 2 trial evaluating the safety, tumor response and duratio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:3/5/2015)... 2015 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today it will report fourth ... open on Wednesday, March 25, 2015, followed by ... Eastern. Conference Call & Webcast: ... Domestic: , 800-753-9057International: , 913-981-5571Conference ID: , ...
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März ... Gates Stiftung und das deutsche biopharmazeutische Unternehmen ... 46 Millionen Euro (52 Millionen US-Dollar) in ... Bereich der medizinisch angewandten Messenger-RNA (mRNA). Auf ... Ansätze zur Behandlung von Krankheiten und zum ...
(Date:3/5/2015)...  As the pharmaceutical industry works to address ... professionals are placing a significant emphasis on company ... by LRN, the leader in Ethics & Compliance ... respondents expressed that clarity on company values is ... training programs (57%), trumping understanding of the PhRMA ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... 2010 Results from the VeriStrat analysis of a ... with sorafenib in patients with advanced non-small cell lung ... Symposium on Molecular Targets in Cancer Therapeutics being held ... the VU Medical Center, Amsterdam, The Netherlands.  The intention ...
... SAN DIEGO, Nov. 19, 2010 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel anti-cancer therapeutics, announced today ... the Listing Qualifications Staff of The NASDAQ Stock Market ... $10 million stockholders, equity requirement for continued listing on ...
Cached Medicine Technology:VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 2VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 3Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 2Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 3
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: